Rituximab in Patients With Relapsed or Refractory TTP-HUS
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00531089 |
Recruitment Status : Unknown
Verified September 2007 by McMaster University.
Recruitment status was: Recruiting
First Posted : September 18, 2007
Last Update Posted : May 19, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Thrombotic Thrombocytopenic Purpura Hemolytic Uremic Syndrome | Drug: Rituximab | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients With Relapsed/Refractory Thrombotic Thrombocytopenic Purpura (TTP) - Hemolytic Uremic Syndrome (HUS) |
Study Start Date : | December 2007 |
Estimated Primary Completion Date : | January 2011 |
Estimated Study Completion Date : | January 2011 |
Arm | Intervention/treatment |
---|---|
Experimental: Study group
All patients in the study will be in the study group and will receive rituximab. There is no "control" arm.
|
Drug: Rituximab
Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.
Other Name: Rituxan, rituximab |
- The proportion of patients achieving all: (1) platelet count >150x109/L; (2) LDH < 1.5 x normal; (3) no requirement for plasma exchange therapy; (4) asymptomatic. [ Time Frame: 8 weeks after initiation of therapy ]
- proportion of patients with platelet count greater than 150 x 109/L [ Time Frame: 8 weeks ]
- proportion of patients with LDH < 1.5 X normal [ Time Frame: 8 weeks ]
- proportion of patients with no requirement for plasma exchange therapy [ Time Frame: 8 weeks ]
- proportion of patients who are asymptomatic (no new neurological symptoms ans stabilization of previous neurological symptoms [ Time Frame: 8 weeks ]
- clinical response (CR, PR, non-response) [ Time Frame: 52 weeks ]
- frequency of relapse [ Time Frame: 52 weeks ]
- mortality [ Time Frame: 52 weeks ]
- changes from baseline in platelet counts, LDH, ADAMTS13 protease level, ADAMTS13 inhibitor level [ Time Frame: 8, 12, 24, 52 weeks ]
- toxicity and clinical safety as assessed by monitoring of adverse events, laboratory parameters, vital signs during infusion, and immediate tolerability [ Time Frame: 8 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- any patient 18 years or older diagnosed with relapsed or refractory TTP-HUS requiring therapy
Exclusion Criteria:
- alternate cause of hemolytic microangiopathy (evidence of DIC, malignant hypertension, vasculitis, anti-phospholipid antibody syndrome, post-partum acute renal failure)
- congenital or familial TTP
- TTP occuring post-stem cell, bone marrow, or solid organ transplant
- drug-induced TTP
- pregnancy or breast-feeding
- history of hepatitis B or C infection
- prior rituximab treatment
- active or metastatic cancer
- other causes of thrombocytopenia such as ITP, myelodysplastic syndrome, confirmed or suspected drug-induced thrombocytopenia
- refusal to receive blood products
- hypersensitivity to blood products, plasma products, murine proteins, or any component of the Rituximab formulation
- geographic inaccessibility
- co-morbid illness limiting life expectancy to less than 2 months independent of TTP
- failure to provide written informed consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00531089
Contact: Kathryn E Webert, MD | 905-521-2100 ext 76733 | webertk@mcmaster.ca |
Canada, Alberta | |
Foothills Medical Centre, Calgary Health REgion Apheresis Service | Not yet recruiting |
Calgary, Alberta, Canada, T2N 2T9 | |
Contact: John Klassen, MD 403-944-4712 john.klassen@calgaryhealthregion.ca | |
Principal Investigator: John Klassen, MD | |
University of Alberta Hospital | Not yet recruiting |
Edmonton, Alberta, Canada | |
Principal Investigator: L Larratt, MD | |
Canada, British Columbia | |
Vancouver General Hospital | Recruiting |
Vancouver, British Columbia, Canada, V5Z1M9 | |
Contact: Paul Yenson, Dr. 604-875-4863 pyenson@bccancer.bc.ca | |
Contact: Lisa Basque 604-875-4111 ext 69014 lbasque@bccancer.bc.ca | |
Principal Investigator: Paul Yenson, Dr | |
Canada, Manitoba | |
Winnipeg Regional Health Authority, Apheresis Department | Not yet recruiting |
Winnipeg, Manitoba, Canada, R3E 0T2 | |
Contact: Cathy Moltzan, MD 204-787-4269 cmoltzan@sbgh.mb.ca | |
Principal Investigator: Cathy Moltzan, MD | |
Canada, New Brunswick | |
St. John Regional Hospital | Not yet recruiting |
St. John, New Brunswick, Canada, E2K5S9 | |
Contact: Sean Dolan, MD 506-634-1201 | |
Principal Investigator: Sean Dolan, MD | |
Canada, Ontario | |
Hamilton Health Sciences | Recruiting |
Hamilton, Ontario, Canada, L8N 3Z5 | |
Contact: Julie Carruthers 905-525-9140 ext 22942 carrutj@mcmaster.ca | |
Principal Investigator: Kathryn E Webert, MD | |
Principal Investigator: Ronan Roley, MD | |
Sub-Investigator: Donald M Arnold, MD | |
London Health Sciences Centre, Westminister Campus | Recruiting |
London, Ontario, Canada, N6A4G5 | |
Contact: Clark F William, MD 519-685-8500 ext 57238 william.clark@lhsc.on.ca | |
Principal Investigator: William F Clark, MD | |
Princess Margaret Hospital, ABMT/Apheresis Unit | Recruiting |
Toronto, Ontario, Canada, M5G2M9 | |
Contact: David Barth, MD 416-946-4688 david.barth@uhn.on.ca | |
Principal Investigator: David Barth, MD | |
Canada, Quebec | |
Hopital Charles Lemoyne | Not yet recruiting |
Greenfield Park, Quebec, Canada | |
Contact: S Fox, MD 450-466-5000 | |
Principal Investigator: S Fox, MD | |
Hopital du Sacre-Coeur de Montreal | Not yet recruiting |
Montreal, Quebec, Canada, H4J1C5 | |
Contact: J P Moquin, MD 514-338-2222 ext 3368 jp.moquin@videotron.ca | |
Principal Investigator: J P Moquin, MD | |
Canada, Saskatchewan | |
St. Paul's Hospital Apheresis Unit | Recruiting |
Saskatoon, Saskatchewan, Canada, S7M 0Z9 | |
Contact: Ahmed Shoker, MD 306-655-5934 ahmed.shoker@usask.ca | |
Principal Investigator: Ahmed Shoker, MD |
Principal Investigator: | Kathryn E Webert, E | Hamilton Health Sciences Corporation | |
Principal Investigator: | Ronan Foley, MD | Hamilton Health Sciences Corporation | |
Study Director: | Gail Rock, MD | Canadian Apheresis Group | |
Study Director: | William Clark, MD | University of Western Ontario/London Health Sciences | |
Study Director: | David Barth, MD | University of Toronto |
Responsible Party: | Canadian Apheresis Group |
ClinicalTrials.gov Identifier: | NCT00531089 |
Other Study ID Numbers: |
CAG-1 |
First Posted: | September 18, 2007 Key Record Dates |
Last Update Posted: | May 19, 2010 |
Last Verified: | September 2007 |
TTP thrombotic thrombocytopenic purpura HUS hemolytic uremic syndrome plasma exchange |
Azotemia Hemolytic-Uremic Syndrome Purpura Purpura, Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Syndrome Hemolysis Disease Pathologic Processes Blood Coagulation Disorders Hematologic Diseases Hemorrhage Skin Manifestations Thrombotic Microangiopathies Thrombocytopenia |
Blood Platelet Disorders Cytopenia Immune System Diseases Uremia Kidney Diseases Urologic Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Male Urogenital Diseases Anemia, Hemolytic Anemia Thrombophilia Rituximab Antineoplastic Agents, Immunological |